Staodyn
This article was originally published in The Gray Sheet
Executive Summary
Firm's board of directors approves the repurchase of up to 200,000 shares of common "as a result of what the company views as the depressed market price of its common stock," the electromedical treatment devices manufacturer announces. The board also extends to Feb. 28, 1995 the expiration date of the firm's currently outstanding warrants issued in June 1991 and expiring June 19, 1994. Two warrants can be used to buy one share of Staodyn common stock at $5 per share; 920,000 of these warrants are outstanding. The firm notes it has begun shipping its Dermapulse wound management system to Canada and expects to begin marketing the electrostimulation device in Europe within six months
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.